Загрузка видео...

Не удалось загрузить видео

Возникла проблема при загрузке этого видео. Это может быть связано с временными проблемами сети или видео может быть недоступно.

На главную

Recursion Announces New Clinical Data Across Two Potential First-in-Class Programs, Sanofi Partnership Milestone, and Oversubscribed $200M Offering Today, we announced important progress across our clinical pipeline, partnerships, and capital position—reflecting growing evidence of what our integrated AI-enabled drug discovery platform can deliver. 🚀 REC-4881 | Deep, durable polyp reductions... in FAP In an expanded adult population (18+), 87% of patients achieved polyp burden reductions after 12 weeks (47% median), with 85% remaining below baseline after 12 weeks off treatment. In the upper GI—the area of greatest unmet need—92% achieved reductions (55% median), including two patients with near-complete reductions (≥98%). Of those with reductions, 92% remained below baseline after 12 weeks off treatment. With no approved pharmacologic therapies for FAP, we are targeting registrational trial initiation in 2H 2027, pending FDA discussions. Full data will be presented November 2 at CGA-IGC. 🚀 REC-1245 | Encouraging early activity in heavily pretreated cancer patients Our potential first-in-class oral RBM39 degrader demonstrated three partial responses (two confirmed in endometrial cancer; one unconfirmed in liver cancer) and 91.7% disease control (11/12) at doses ≥45 mg. No dose-limiting toxicities or treatment-related serious adverse events were observed at the selected 45 mg expansion dose. 🚀 Sanofi | First development candidate optioned Two challenging targets, one oral molecule. A potential first-in-class candidate for inflammatory disease, enabled by Recursion’s AI platform and small-molecule chemistry capabilities alongside Sanofi’s expertise. Phase 1 expected in 2027, marking the sixth progress-based milestone across our collaboration. 🚀 $200M Oversubscribed Follow-On Offering | Extending Runway Into 2029 Broad demand from leading healthcare specialists, long-only institutions, and growth investors, including Janus Henderson Investors, Invus, Longaeva Partners, ARK Invest, and Driehaus Capital Management. The financing supports advancement of our clinical pipeline, continued AI engine innovation, and strategic partnerships. Multiple independent proof points. Across diseases, programs, and partnerships. Powered by one integrated AI-enabled engine. Thank you to our employees, collaborators, clinical investigators, patients, and investors who make this progress possible. Links below 👇 Business Update: Sanofi announcement: Public offering:show more

Recursion

17,684 subscribers

636,399 просмотров • 27 дней назад •via X (Twitter)

Наука и технологии

Anya Rossi• Live Now

Private livecam show

Комментарии: 1

Фото профиля سامي

سامي27 дней назад

كفو عليكم شدوا الهمه

Похожие видео

Today, we announce our Q1 2026 business updates and financial results – demonstrating continued momentum across our internal portfolio and partnered programs, with multiple value-driving milestones on track. 🚀 Key proof points include: ▪️ REC-1245 (RBM39 degrader): Early clinical data demonstrate a well-tolerated safety profile and predictable, dose-dependent PK (n=16); dose escalation ongoing with no dose-limiting toxicities observed to date. ▪️ REC-4539 (LSD1 inhibitor): First patient dosed in Phase 1; platform-derived, selective, brain-penetrant profile with a reversible mechanism and shorter predicted half-life aimed at reducing on-target platelet toxicity, supporting differentiation in solid tumors and AML. ▪️ REC-4881 (MEK1/2 inhibitor): Strong Phase 2 efficacy signals and a safety profile consistent with the MEK inhibitor class, with FDA engagement initiated to define a potential registrational pathway and an update expected in 2H26. ▪️ Our joint programs with Sanofi continue advancing towards development candidate designation and earlier stage program milestones in the next 12 months, and we expect to continue to translate biological insights from maps delivered to Roche and Genentech into potential target validation milestones over the next 12 months. As CEO and President Najat Khan says, this “represents a growing set of proof points that demonstrate our ability to translate platform insights into clinical programs. This progress reflects the strength of both our internal pipeline and partnerships, with multiple differentiated programs advancing through our end-to-end AI platform.” Our Q1 Earnings report also highlights our disciplined capital execution: reiterating the 2026 guidance of <$390M operational cash burn, and supporting runway into early 2028 without additional financing. 👉 Join our Earnings Call on Wed., May 6 at 8:00 am ET / 6:00 am MT / 1:00 pm BST, here on X and on: ▪️ YouTube: ▪️ LinkedIn: 👉 Analysts, investors, and the public can submit questions here: 👉 Read the full report:

Recursion

23,615 просмотров • 6 месяцев назад

🔹 AI drug discovery, validated. Recursion recently announced the first clinical validation of its AI-enabled drug discovery platform – positive Phase 1b/2 data for the ongoing TUPELO study evaluating its AI-identified drug, REC-4881, in Familial Adenomatous Polyposis (FAP). This progressive rare disease affects more than 50,000 people in the U.S. and EU and has no FDA-approved treatments. It results in hundreds to thousands of polyps developing in the colon, and requires a lifetime of invasive surveillance and surgery. Recursion used AI not only to deliver the first potential treatment for this disease but also to quantify – for the first time at scale – the true natural progression of polyp burden in the trial-relevant population. It demonstrates the incredible breakthroughs that can come from merging proprietary data and AI – and the tangible impact on patient lives. 👉 See the full study results here:

🔹 AI drug discovery, validated. Recursion recently announced the first clinical validation of its AI-enabled drug discovery platform – positive Phase 1b/2 data for the ongoing TUPELO study evaluating its AI-identified drug, REC-4881, in Familial Adenomatous Polyposis (FAP). This progressive rare disease affects more than 50,000 people in the U.S. and EU and has no FDA-approved treatments. It results in hundreds to thousands of polyps developing in the colon, and requires a lifetime of invasive surveillance and surgery. Recursion used AI not only to deliver the first potential treatment for this disease but also to quantify – for the first time at scale – the true natural progression of polyp burden in the trial-relevant population. It demonstrates the incredible breakthroughs that can come from merging proprietary data and AI – and the tangible impact on patient lives. 👉 See the full study results here:

Recursion

255,879 просмотров • 10 месяцев назад

🚀 Reshaping drug discovery – and the future of medicine – with AI. Recursion CFO Ben Taylor joined the Opto Sessions podcast from CMC Aureon to share how Recursion uses AI, lab automation, biological data, and machine learning to improve the way new medicines are discovered and developed. 💠 They discuss: ▪️How pairing AI with lab automation across biology, chemistry, and clinical technology allows us to move beyond the ~10–12% of the genome currently addressed by approved or in-trial medicines and explore the vast realm of untapped biology. ▪️How Recursion is advancing REC-4881 for patients with familial adenomatous polyposis (FAP) — a progressive condition with no approved medical therapies — after achieving Phase 2 proof-of-concept and demonstrating meaningful reductions in polyp burden. ▪️How Recursion is compressing timelines and improving efficiency with high-quality, ML-ready data to design better molecules with ~90% fewer experimental chemistries and to run smarter, faster clinical trials. 👉 Check out the full conversation:

🚀 Reshaping drug discovery – and the future of medicine – with AI. Recursion CFO Ben Taylor joined the Opto Sessions podcast from CMC Aureon to share how Recursion uses AI, lab automation, biological data, and machine learning to improve the way new medicines are discovered and developed. 💠 They discuss: ▪️How pairing AI with lab automation across biology, chemistry, and clinical technology allows us to move beyond the ~10–12% of the genome currently addressed by approved or in-trial medicines and explore the vast realm of untapped biology. ▪️How Recursion is advancing REC-4881 for patients with familial adenomatous polyposis (FAP) — a progressive condition with no approved medical therapies — after achieving Phase 2 proof-of-concept and demonstrating meaningful reductions in polyp burden. ▪️How Recursion is compressing timelines and improving efficiency with high-quality, ML-ready data to design better molecules with ~90% fewer experimental chemistries and to run smarter, faster clinical trials. 👉 Check out the full conversation:

Recursion

98,892 просмотров • 4 месяцев назад

Today, Recursion reported our 4Q/FY25 business updates and financial results. As CEO and President Najat Khan said, “Recursion has reached an inflection point: moving from proving that AI can participate in drug discovery to demonstrating that an AI-native operating system can generate clinical proof and durable value.” This includes: 🚀 A 5th milestone with Sanofi for a first-in-class Sanofi-partnered oncology program against a historically difficult and novel biological space. This brings the total upfront and progress-based milestones to $134 million to date. Five Recursion discovery program packages have been accepted to date, establishing a growing joint portfolio of novel AI-driven small molecules for immunology and oncology. 🚀 The first AI-enabled clinical validation of the Recursion OS platform in our FAP program, demonstrating translation from AI-driven biological insight to meaningful patient outcomes. We also have multiple clinical and preclinical programs advancing with defined milestones. 🚀 New preclinical efficacy data for REC-7735, a potential best-in-class PI3K⍺ H1047R inhibitor, precision designed with 242 compounds synthesized from first novel hit to REC-7735 in 10 months using the Recursion OS platform. REC-7735 demonstrates >100-fold selectivity for the H1074R mutation over WT PI3K⍺ suggesting potential improved tolerability over current inhibitors and is currently in IND-enabling studies. 🚀 $754 million of cash and cash equivalents. We exceeded our original cost savings guidance and now expect runway into early 2028, without additional financing. 👉 Read the full business updates here: 🔹 Tune in to our Earnings Call today, February 25, 2026 at 8:00 am ET / 6:00 am MT / 1:00 pm GMT, here on X, or on: ▪️ YouTube: ▪️ LinkedIn:

Today, Recursion reported our 4Q/FY25 business updates and financial results. As CEO and President Najat Khan said, “Recursion has reached an inflection point: moving from proving that AI can participate in drug discovery to demonstrating that an AI-native operating system can generate clinical proof and durable value.” This includes: 🚀 A 5th milestone with Sanofi for a first-in-class Sanofi-partnered oncology program against a historically difficult and novel biological space. This brings the total upfront and progress-based milestones to $134 million to date. Five Recursion discovery program packages have been accepted to date, establishing a growing joint portfolio of novel AI-driven small molecules for immunology and oncology. 🚀 The first AI-enabled clinical validation of the Recursion OS platform in our FAP program, demonstrating translation from AI-driven biological insight to meaningful patient outcomes. We also have multiple clinical and preclinical programs advancing with defined milestones. 🚀 New preclinical efficacy data for REC-7735, a potential best-in-class PI3K⍺ H1047R inhibitor, precision designed with 242 compounds synthesized from first novel hit to REC-7735 in 10 months using the Recursion OS platform. REC-7735 demonstrates >100-fold selectivity for the H1074R mutation over WT PI3K⍺ suggesting potential improved tolerability over current inhibitors and is currently in IND-enabling studies. 🚀 $754 million of cash and cash equivalents. We exceeded our original cost savings guidance and now expect runway into early 2028, without additional financing. 👉 Read the full business updates here: 🔹 Tune in to our Earnings Call today, February 25, 2026 at 8:00 am ET / 6:00 am MT / 1:00 pm GMT, here on X, or on: ▪️ YouTube: ▪️ LinkedIn:

Recursion

11,878 просмотров • 8 месяцев назад

Today, we announced the completion of enrollment in our global BROADEN2 Phase 2b trial of KT-621, our investigational, first-in-class, oral STAT6 degrader, in atopic dermatitis, nearly six months ahead of anticipated timelines. This milestone enables us to accelerate our expected topline data readout to year-end 2026 and continue advancing KT-621 as a potential oral treatment option for patients living with atopic dermatitis and other Type 2 inflammatory diseases. Read more in our press release:

Today, we announced the completion of enrollment in our global BROADEN2 Phase 2b trial of KT-621, our investigational, first-in-class, oral STAT6 degrader, in atopic dermatitis, nearly six months ahead of anticipated timelines. This milestone enables us to accelerate our expected topline data readout to year-end 2026 and continue advancing KT-621 as a potential oral treatment option for patients living with atopic dermatitis and other Type 2 inflammatory diseases. Read more in our press release:

Kymera Therapeutics

21,777 просмотров • 4 месяцев назад

We’re excited to announce positive results from our BroADen Phase 1b clinical trial of KT-621, our investigational, first-in-class, oral STAT6 degrader, in patients with moderate to severe atopic dermatitis. The data provide a powerful validation of our industry-leading STAT6 degrader program and help accelerate our goal to deliver novel oral medicines to millions of patients around the world. Our deepest thanks to the patients, investigators, and the incredible Kymera team whose dedication made this significant milestone possible. Read more about the promising KT-621 data in our press release and join our live video webcast at 8:00AM ET today: #RevolutionizingImmunology

We’re excited to announce positive results from our BroADen Phase 1b clinical trial of KT-621, our investigational, first-in-class, oral STAT6 degrader, in patients with moderate to severe atopic dermatitis. The data provide a powerful validation of our industry-leading STAT6 degrader program and help accelerate our goal to deliver novel oral medicines to millions of patients around the world. Our deepest thanks to the patients, investigators, and the incredible Kymera team whose dedication made this significant milestone possible. Read more about the promising KT-621 data in our press release and join our live video webcast at 8:00AM ET today: #RevolutionizingImmunology

Kymera Therapeutics

15,395 просмотров • 11 месяцев назад

🚀 How Recursion used AI to identify a novel approach for potentially treating the rare disease Familial Adenomatous Polyposis (FAP). A new video shares the story of Recursion’s investigational drug REC-4881 for the rare disease FAP which affects more than 50,000 people in the US and EU5 and has no approved medicines. Patients with this disease develop hundreds to thousands of polyps in their early teens to 20s that, if left untreated, have a nearly 100% risk of developing into colon cancer. ⬇️ Here’s how we did it: ▪️ Using the Recursion OS platform to analyze cell morphology, we tested thousands of compounds to find drugs that restored FAP-diseased cells to a healthy state. ▪️ This led us to REC-4881 — a drug that blocks a biological pathway called MEK1/2 – a new approach for treating FAP that had not been investigated clinically before. ▪️ Now, we’re using the full Recursion OS 2.0 platform — including our ClinTech real-world evidence – to fully understand disease burden and guide our clinical strategy, allowing us to expand patient eligibility for our trial. 💡 The takeaway: This program is the first clinical validation of the Recursion OS, and demonstrates our ability to translate unbiased phenotypic insights into potentially differentiated treatments for diseases with high unmet need. 👉 Read the full summary data in our December 8, 2025 press release here:

🚀 How Recursion used AI to identify a novel approach for potentially treating the rare disease Familial Adenomatous Polyposis (FAP). A new video shares the story of Recursion’s investigational drug REC-4881 for the rare disease FAP which affects more than 50,000 people in the US and EU5 and has no approved medicines. Patients with this disease develop hundreds to thousands of polyps in their early teens to 20s that, if left untreated, have a nearly 100% risk of developing into colon cancer. ⬇️ Here’s how we did it: ▪️ Using the Recursion OS platform to analyze cell morphology, we tested thousands of compounds to find drugs that restored FAP-diseased cells to a healthy state. ▪️ This led us to REC-4881 — a drug that blocks a biological pathway called MEK1/2 – a new approach for treating FAP that had not been investigated clinically before. ▪️ Now, we’re using the full Recursion OS 2.0 platform — including our ClinTech real-world evidence – to fully understand disease burden and guide our clinical strategy, allowing us to expand patient eligibility for our trial. 💡 The takeaway: This program is the first clinical validation of the Recursion OS, and demonstrates our ability to translate unbiased phenotypic insights into potentially differentiated treatments for diseases with high unmet need. 👉 Read the full summary data in our December 8, 2025 press release here:

Recursion

11,994 просмотров • 9 месяцев назад

Today we’re reporting interim Phase 1 clinical data for our REC-617 monotherapy trial – with plans to expand into combination studies in advanced solid tumors. At the AACR Special Conference in Cancer Research, CSO David Hallett shared interim monotherapy dose-escalation data from the Phase 1/2 study (ELUCIDATE) of REC-617, a selective CDK7 inhibitor, in advanced solid tumors. 🔹The interim Phase 1 clinical data for REC-617 included: ▫️Dose-linear pharmacokinetics (PK) with rapid absorption and robust pharmacodynamic (PD) biomarker modulation, suggesting substantial target engagement; ▫️Confirmed partial response (PR) during monotherapy dose-escalation in a patient with platinum-resistant ovarian cancer, treated with 4 lines of prior therapy in an advanced setting, with durable response ongoing after more than 6 months of treatment; ▫️In 4 additional patients, a best response of stable disease (SD) for up to 6 months of treatment. Dr. Hallett noted: “Cell cycle dysregulation and transcriptional 'addiction' are both hallmarks of many aggressive cancers. By inhibiting CDK7, we have the potential to target both mechanisms while fine tuning the therapeutic index.” "These initial findings for REC-617 represent an exciting step forward in the development of CDK7 inhibitors, with a favorable PK/PD profile and a durable confirmed partial response observed in dose escalation in a highly pre-treated patient population," said Najat Khan, Ph.D., Chief R&D Officer and Chief Commercial Officer. “Designed using our AI-powered OS platform, REC-617 reflects our focus on enhancing the therapeutic index to deliver more effective and safer treatment options for patients. We are eager to continue this momentum in dose escalation and to initiate the next phase of the program next year." 👉Learn more: 🔹Join the Update Call: Tomorrow, Tues., Dec. 10 at 8:30am ET, Dr. Hallett and Dr. Khan will hold a live Update Call webcast to present the preliminary data. ▫️Submit questions for the Update Call here: ▫️Tune in to the Update Call here on X or on: LinkedIn: YouTube:

Recursion

11,902 просмотров • 1 год назад

NEWS: Update on Ivermectin in Cancer Clinical Trials in Florida 😃 There were 2 clinical trials in 2025, there are 6 clinical trials in 2026 and hopefully 10-12 clinical trials in 2027! One of them will be completed next month! Very exciting times for cancer patients! 🙏

NEWS: Update on Ivermectin in Cancer Clinical Trials in Florida 😃 There were 2 clinical trials in 2025, there are 6 clinical trials in 2026 and hopefully 10-12 clinical trials in 2027! One of them will be completed next month! Very exciting times for cancer patients! 🙏

William Makis MD

176,063 просмотров • 1 месяц назад

We are thrilled to share positive topline data from our ELEVATE IPF Phase 2b trial evaluating deupirfenidone (LYT-100) for the treatment of idiopathic pulmonary fibrosis (#IPF), a progressive and fatal lung disease. Our trial met the primary and key secondary endpoints, with deupirfenidone demonstrating the potential to serve as a new standard of care. Over 26 weeks, the highest dose of deupirfenidone studied was generally well-tolerated and reduced lung function decline to levels that approach natural lung function decline in healthy adults over sixty—a first for any investigational or approved treatment for IPF. We’re incredibly excited for what deupirfenidone could offer the IPF community, which urgently needs new treatment options with better efficacy that don’t compromise on tolerability. A heartfelt thank you to everyone who participated in the ELEVATE IPF trial, including patients, caregivers, clinical trial sites, and advocacy groups. Your courage, dedication and expertise make progress possible, and we are grateful for your trust and partnership. Read more in today’s press release:

We are thrilled to share positive topline data from our ELEVATE IPF Phase 2b trial evaluating deupirfenidone (LYT-100) for the treatment of idiopathic pulmonary fibrosis (#IPF), a progressive and fatal lung disease. Our trial met the primary and key secondary endpoints, with deupirfenidone demonstrating the potential to serve as a new standard of care. Over 26 weeks, the highest dose of deupirfenidone studied was generally well-tolerated and reduced lung function decline to levels that approach natural lung function decline in healthy adults over sixty—a first for any investigational or approved treatment for IPF. We’re incredibly excited for what deupirfenidone could offer the IPF community, which urgently needs new treatment options with better efficacy that don’t compromise on tolerability. A heartfelt thank you to everyone who participated in the ELEVATE IPF trial, including patients, caregivers, clinical trial sites, and advocacy groups. Your courage, dedication and expertise make progress possible, and we are grateful for your trust and partnership. Read more in today’s press release:

PureTech

10,917 просмотров • 1 год назад

Today marks a pivotal moment for Isomorphic Labs. We have secured $2.1 Billion in our second external funding round, led by Thrive Capital. They are joined at the table by Alphabet, GV and new investors MGX, Temasek, CapitalG and the UK Sovereign AI Fund. This milestone accelerates our ability to build the pioneering novel AI models that power our AI drug design engine (IsoDDE) and deploy them at scale: delivering scientific breakthroughs with a precision previously thought impossible, accelerating and expanding our pipeline of therapeutic programs toward the clinic. All with the ultimate goal of delivering life-changing new medicines to patients. Moving forward, we will scale our drug candidate pipelines across multiple therapeutic areas, expand our global footprint, and push the boundaries of frontier AI research to power our drug design engine. Deeply grateful to everyone sharing our vision to solve all disease with AI. Let’s build the future of medicine. Read the full announcement here:

Today marks a pivotal moment for Isomorphic Labs. We have secured $2.1 Billion in our second external funding round, led by Thrive Capital. They are joined at the table by Alphabet, GV and new investors MGX, Temasek, CapitalG and the UK Sovereign AI Fund. This milestone accelerates our ability to build the pioneering novel AI models that power our AI drug design engine (IsoDDE) and deploy them at scale: delivering scientific breakthroughs with a precision previously thought impossible, accelerating and expanding our pipeline of therapeutic programs toward the clinic. All with the ultimate goal of delivering life-changing new medicines to patients. Moving forward, we will scale our drug candidate pipelines across multiple therapeutic areas, expand our global footprint, and push the boundaries of frontier AI research to power our drug design engine. Deeply grateful to everyone sharing our vision to solve all disease with AI. Let’s build the future of medicine. Read the full announcement here:

Isomorphic Labs

310,089 просмотров • 6 месяцев назад

A few days ago, we learned that the first patient in the U.S., to our knowledge, has been dosed with lidocaine for their breast cancer treatment. Just six weeks ago, we learned about the potential connection between lidocaine and improved breast cancer outcomes from a groundbreaking clinical trial of 1,600 patients conducted in India. That study showed a potential 30% reduction in five-year mortality for patients who received lidocaine injections into their tumors before surgery. Since then, we've engaged in discussions with specialists and researchers, and what we’ve discovered has been surprising —no one seemed to be using this approach, despite the data available. The other day, one of those conversations turned into action. A doctor we spoke to decided to inject a tumor with lidocaine before removing it, marking a critical first step toward translating global insights into real-world patient care. This moment excites us because it shows the power of accelerating drug repurposing insights into clinical practice. At Every Cure, this is exactly what drives us: identifying overlooked opportunities and ensuring they reach patients who need them most—quickly and efficiently. #medtwitter

A few days ago, we learned that the first patient in the U.S., to our knowledge, has been dosed with lidocaine for their breast cancer treatment. Just six weeks ago, we learned about the potential connection between lidocaine and improved breast cancer outcomes from a groundbreaking clinical trial of 1,600 patients conducted in India. That study showed a potential 30% reduction in five-year mortality for patients who received lidocaine injections into their tumors before surgery. Since then, we've engaged in discussions with specialists and researchers, and what we’ve discovered has been surprising —no one seemed to be using this approach, despite the data available. The other day, one of those conversations turned into action. A doctor we spoke to decided to inject a tumor with lidocaine before removing it, marking a critical first step toward translating global insights into real-world patient care. This moment excites us because it shows the power of accelerating drug repurposing insights into clinical practice. At Every Cure, this is exactly what drives us: identifying overlooked opportunities and ensuring they reach patients who need them most—quickly and efficiently. #medtwitter

David Fajgenbaum, MD

55,828 просмотров • 1 год назад

Today we’re announcing the $600M Formation Bio Drug Development Accelerator Fund. linhao and I started Formation Bio because we believed the biggest bottleneck in bringing new medicines to patients wasn’t drug discovery, but drug development. As AI dramatically accelerates discovery, that bottleneck is only becoming more acute. Without the capital and capacity to advance promising drugs through clinical trials, much of that progress won’t translate into medicines for patients. Our new Fund brings together dedicated capital, drug development expertise, and AI-powered development capabilities to acquire promising drugs and advance them through the clinic.

Today we’re announcing the $600M Formation Bio Drug Development Accelerator Fund. linhao and I started Formation Bio because we believed the biggest bottleneck in bringing new medicines to patients wasn’t drug discovery, but drug development. As AI dramatically accelerates discovery, that bottleneck is only becoming more acute. Without the capital and capacity to advance promising drugs through clinical trials, much of that progress won’t translate into medicines for patients. Our new Fund brings together dedicated capital, drug development expertise, and AI-powered development capabilities to acquire promising drugs and advance them through the clinic.

Ben Liu

244,633 просмотров • 14 дней назад

Johnny Lubin was one of the youngest patients in the clinical trial supporting today’s approval of the first CRISPR treatment in the US, one of two therapies approved today for sickle cell. He told us how the therapy has changed his life:

Johnny Lubin was one of the youngest patients in the clinical trial supporting today’s approval of the first CRISPR treatment in the US, one of two therapies approved today for sickle cell. He told us how the therapy has changed his life:

Meg Tirrell

26,921 просмотров • 2 лет назад

We’re announcing that Forus has raised a $150M Series C at a $3B valuation to build the AI network for medicine. Medicine will remain one of the world’s most important industries until humanity achieves immortality, and we are only at the beginning of a new era in what it can do. GLP-1s are changing obesity and cardiometabolic disease. Gene therapies can treat diseases at their genetic source. New cancer treatments are turning diagnoses that were once fatal into diseases people can live with. AI is enabling us to discover of new drugs even faster. But discovery is only the beginning. It still takes more than a decade and billions of dollars to turn a new molecule into an approved medicine, and once it reaches market, more than a third of patients prescribed specialty treatments never receive their first dose. Forus is creating the AI network to accelerate the entire medicine pipeline, from development and launch through prescription and treatment. We connect the companies creating medicines with the doctors who prescribe them and the patients who need them. Today, Forus supports millions of people across all 50 states and is already used by providers to treat patients in 85% of U.S. residential ZIP codes. 9 of the top 15 global biopharma companies work with us, alongside many fast-growing biotechs. Our goal is to put Forus in every doctor’s office in the country and unlock an order of magnitude more medicine for society. There is a generational opportunity to rethink how new medicine reaches people. Forus is becoming how medicine moves from discovery to treatment in America, and as we scale, we’ll become the most important company in life sciences. Forus is not constrained by capital or customer demand; we are constrained by the talent and capacity of our team. To take on the opportunity in front of us, we need exceptional engineers and operators in New York who want to move fast and help us make something that matters. Come build with us. Our Series C was led by Bain Capital Ventures, with Thrive Capital, General Catalyst, Accel, Redpoint, BoxGroup, Pear VC, Vast Ventures, and SV Angel investing alongside them.

We’re announcing that Forus has raised a $150M Series C at a $3B valuation to build the AI network for medicine. Medicine will remain one of the world’s most important industries until humanity achieves immortality, and we are only at the beginning of a new era in what it can do. GLP-1s are changing obesity and cardiometabolic disease. Gene therapies can treat diseases at their genetic source. New cancer treatments are turning diagnoses that were once fatal into diseases people can live with. AI is enabling us to discover of new drugs even faster. But discovery is only the beginning. It still takes more than a decade and billions of dollars to turn a new molecule into an approved medicine, and once it reaches market, more than a third of patients prescribed specialty treatments never receive their first dose. Forus is creating the AI network to accelerate the entire medicine pipeline, from development and launch through prescription and treatment. We connect the companies creating medicines with the doctors who prescribe them and the patients who need them. Today, Forus supports millions of people across all 50 states and is already used by providers to treat patients in 85% of U.S. residential ZIP codes. 9 of the top 15 global biopharma companies work with us, alongside many fast-growing biotechs. Our goal is to put Forus in every doctor’s office in the country and unlock an order of magnitude more medicine for society. There is a generational opportunity to rethink how new medicine reaches people. Forus is becoming how medicine moves from discovery to treatment in America, and as we scale, we’ll become the most important company in life sciences. Forus is not constrained by capital or customer demand; we are constrained by the talent and capacity of our team. To take on the opportunity in front of us, we need exceptional engineers and operators in New York who want to move fast and help us make something that matters. Come build with us. Our Series C was led by Bain Capital Ventures, with Thrive Capital, General Catalyst, Accel, Redpoint, BoxGroup, Pear VC, Vast Ventures, and SV Angel investing alongside them.

Sahir

276,427 просмотров • 2 месяцев назад

For over a century, across generations, trust has been the foundation of every milestone that we have achieved. From our first branch in Baroda, we have grown to become India's International Bank. Every milestone in our journey has been made possible by the trust and support of our customers, employees, partners, investors, and stakeholders. As we celebrate our 119ᵗʰ Foundation Year, we honour this enduring legacy and reaffirm our commitment to empowering progress, creating opportunities, and serving generations to come with the same spirit of trust. #BankofBaroda #LeadingWithTrust #bobturns119

For over a century, across generations, trust has been the foundation of every milestone that we have achieved. From our first branch in Baroda, we have grown to become India's International Bank. Every milestone in our journey has been made possible by the trust and support of our customers, employees, partners, investors, and stakeholders. As we celebrate our 119ᵗʰ Foundation Year, we honour this enduring legacy and reaffirm our commitment to empowering progress, creating opportunities, and serving generations to come with the same spirit of trust. #BankofBaroda #LeadingWithTrust #bobturns119

Bank of Baroda

17,724 просмотров • 3 месяцев назад

I am told this therapy will be available across the country in major cancer hospitals, providing new hope to patients and their families. Moreover, this affordable treatment can be made available to all patients across the world. That will be in tune with our vision of “Vasudhaiva Kutumbakam”.

I am told this therapy will be available across the country in major cancer hospitals, providing new hope to patients and their families. Moreover, this affordable treatment can be made available to all patients across the world. That will be in tune with our vision of “Vasudhaiva Kutumbakam”.

President of India

158,564 просмотров • 2 лет назад

Ivermectin and Mebendazole in Cancer Patients The Clinical Benefit Ratio Complete Response + Partial Response + Stable Disease / Total Patients (CBR) was 84.4% Overall, it is estimated that annual costs of standard chemotherapies average $111,000 per year. Background: Drug repurposing offers a pathway to identify accessible, low-toxicity cancer therapies. Ivermectin and mebendazole have demonstrated multi-target anti-cancer activity. This paper evaluates real-world patient-reported outcomes, safety, and adherence in a cohort of cancer patients utilizing this combination protocol. Methods: Prospective observational cohort of 197 cancer patients, who were prescribed ivermectin and mebendazole off-label through telemedicine (platform by licensed U.S. healthcare providers) Participants received compounded oral capsules containing 25 mg ivermectin and 250 mg mebendazole. Data were collected via voluntary, standardized digital surveys at baseline and at approximately 6-month follow-up. Of the initial cohort (N = 197), baseline characteristics, including cancer type and disease status, were assessed. A total of 122 participants completed the follow-up survey (61.9% response rate) Results: Mean age of 67 years, (52.3% male, 47.7% female). Cancer types included Prostate 27.9% Breast 18.3% Lung 8.6% Colon 5.1% Urologic 4.6% Pancreatic 3.0% Liver 2.5% Gynaecologic 2.5% Hematologic 2.5% Median duration since initial diagnosis, 1.2 years 37.1% experiencing active disease progression. 6-month follow-up Medication adherence, 86.9% Full initial 90-capsule ivermectin-mebendazole prescription. The Clinical Benefit Ratio Complete Response + Partial Response + Stable Disease / Total Patients (CBR) was 84.4% Notably, 48.4% of cohort, strongest positive outcomes: Regression, 15.6% No current evidence of disease (NED), 32.8% Disease stability, 36.1% Disease progression, 15.6% No significant dose-response association was observed for cancer outcomes (p = 0.91), without a clear dose-response gradient for efficacy. Side effects Mild side effects (primarily gastrointestinal), 25.4% (93.6% of those affected continued treatment through minor dose adjustments) Concurrent conventional therapies Chemotherapy, 27.9% Radiation therapy, 21.3% Surgery, 19.7% Adjunctive interventions such as supplement use, 49.2% Dietary modification, 37.7% Conclusions: In this prospective real-world cohort, the combination of ivermectin and mebendazole was associated with high rates of self-reported clinical benefit, with nearly half of participants reporting tumours regression or no current evidence of disease across a heterogeneous population of cancer patients. These findings provide a compelling clinical signal that these well-tolerated, repurposed agents may offer therapeutic benefit. However, observational design, reliance on self-reported outcomes, and potential for selection bias and uncontrolled confounding, these findings should be interpreted as hypothesis-generating. Urgent prospective, randomized, placebo-controlled clinical trials Validate these observations and further define optimal dosing strategies. Mechanism (pharmacodynamics) Ivermectin and mebendazole are antiparasitic agents, demonstrated highly promising anti-cancer activity. Ivermectin Shown to exert over 14 distinct anti-cancer mechanisms across more than 12 cancer types, inhibiting cancer cell proliferation, metastasis, angiogenesis, mitochondrial function. Has demonstrated excellent safety in cancer patients (including those actively undergoing chemotherapy) Ivermectin and mebendazole selectively target cancer stem cells Mebendazole Microtubule disruption, leading to effective cell cycle arrest Potent induction of apoptosis Significant inhibition of tumour growth Inhibition of angiogenesis Disruption of glucose uptake When used together Target non-overlapping pathways, resulting in synergistic tumour regression, cancer stem cell depletion, and reversal of multidrug resistance in multiple in vitro and in vivo models Biodistribution, ivermectin and mebendazole document excellent tissue penetration

Ivermectin and Mebendazole in Cancer Patients The Clinical Benefit Ratio Complete Response + Partial Response + Stable Disease / Total Patients (CBR) was 84.4% Overall, it is estimated that annual costs of standard chemotherapies average $111,000 per year. Background: Drug repurposing offers a pathway to identify accessible, low-toxicity cancer therapies. Ivermectin and mebendazole have demonstrated multi-target anti-cancer activity. This paper evaluates real-world patient-reported outcomes, safety, and adherence in a cohort of cancer patients utilizing this combination protocol. Methods: Prospective observational cohort of 197 cancer patients, who were prescribed ivermectin and mebendazole off-label through telemedicine (platform by licensed U.S. healthcare providers) Participants received compounded oral capsules containing 25 mg ivermectin and 250 mg mebendazole. Data were collected via voluntary, standardized digital surveys at baseline and at approximately 6-month follow-up. Of the initial cohort (N = 197), baseline characteristics, including cancer type and disease status, were assessed. A total of 122 participants completed the follow-up survey (61.9% response rate) Results: Mean age of 67 years, (52.3% male, 47.7% female). Cancer types included Prostate 27.9% Breast 18.3% Lung 8.6% Colon 5.1% Urologic 4.6% Pancreatic 3.0% Liver 2.5% Gynaecologic 2.5% Hematologic 2.5% Median duration since initial diagnosis, 1.2 years 37.1% experiencing active disease progression. 6-month follow-up Medication adherence, 86.9% Full initial 90-capsule ivermectin-mebendazole prescription. The Clinical Benefit Ratio Complete Response + Partial Response + Stable Disease / Total Patients (CBR) was 84.4% Notably, 48.4% of cohort, strongest positive outcomes: Regression, 15.6% No current evidence of disease (NED), 32.8% Disease stability, 36.1% Disease progression, 15.6% No significant dose-response association was observed for cancer outcomes (p = 0.91), without a clear dose-response gradient for efficacy. Side effects Mild side effects (primarily gastrointestinal), 25.4% (93.6% of those affected continued treatment through minor dose adjustments) Concurrent conventional therapies Chemotherapy, 27.9% Radiation therapy, 21.3% Surgery, 19.7% Adjunctive interventions such as supplement use, 49.2% Dietary modification, 37.7% Conclusions: In this prospective real-world cohort, the combination of ivermectin and mebendazole was associated with high rates of self-reported clinical benefit, with nearly half of participants reporting tumours regression or no current evidence of disease across a heterogeneous population of cancer patients. These findings provide a compelling clinical signal that these well-tolerated, repurposed agents may offer therapeutic benefit. However, observational design, reliance on self-reported outcomes, and potential for selection bias and uncontrolled confounding, these findings should be interpreted as hypothesis-generating. Urgent prospective, randomized, placebo-controlled clinical trials Validate these observations and further define optimal dosing strategies. Mechanism (pharmacodynamics) Ivermectin and mebendazole are antiparasitic agents, demonstrated highly promising anti-cancer activity. Ivermectin Shown to exert over 14 distinct anti-cancer mechanisms across more than 12 cancer types, inhibiting cancer cell proliferation, metastasis, angiogenesis, mitochondrial function. Has demonstrated excellent safety in cancer patients (including those actively undergoing chemotherapy) Ivermectin and mebendazole selectively target cancer stem cells Mebendazole Microtubule disruption, leading to effective cell cycle arrest Potent induction of apoptosis Significant inhibition of tumour growth Inhibition of angiogenesis Disruption of glucose uptake When used together Target non-overlapping pathways, resulting in synergistic tumour regression, cancer stem cell depletion, and reversal of multidrug resistance in multiple in vitro and in vivo models Biodistribution, ivermectin and mebendazole document excellent tissue penetration

Joe Tippens

10,953 просмотров • 4 месяцев назад

Shocking results, hope restored for cancer patients. Cancer vanished in 100% of the patients, after 6 months trial with a drug, dostarlimab, with no significant side effects, first time in history of cancer. Colorectal/rectal cancer the 5th commonest cancer in Africa, and usually by the time its diagnosed it would have spread throughout the body giving low survival rates with the traditional treatment.

Shocking results, hope restored for cancer patients. Cancer vanished in 100% of the patients, after 6 months trial with a drug, dostarlimab, with no significant side effects, first time in history of cancer. Colorectal/rectal cancer the 5th commonest cancer in Africa, and usually by the time its diagnosed it would have spread throughout the body giving low survival rates with the traditional treatment.

Dr. Misheck Ruwende

107,513 просмотров • 3 лет назад